ArticleLife (Basel, Switzerland)2025
Psoriasis and Seborrheic Keratoses: Insights from Biologic Therapy and Skin Imaging.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Knowledge, Attitudes, and Practices Among Patients with Seborrheic Dermatitis: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Rare Dermoscopic Vascular Manifestations of Clonal Seborrheic Keratosis: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Psoriasis is one of the most frequent immune-mediated chronic inflammatory cutaneous disease that exerts a considerable psychological impact, including low self-esteem, stigmatization, and depression. In recent years, biologic therapies have substantially transformed the therapeutic landscape for individuals with moderate-to-severe psoriasis, shifting treatment towards a more targeted and personalized approach. Seborrheic keratoses (SKs) are common benign skin lesions, and their association with psoriasis and biologic therapy remains poorly understood. Our retrospective study evaluated a small cohort of patients with moderate-to-severe psoriasis undergoing biologic therapy at a tertiary dermatology center in Southeastern Europe to evaluate potential correlations with SK development. Smokers had fewer SKs, whereas postmenopausal women and osteoporosis patients had significantly higher SK counts, implicating hormonal influences. PUVA therapy was linked to an increased SK count, whereas UVB and methotrexate treatments had a lesser effect. These findings suggest that biologic therapy and systemic factors may influence SK development, emphasizing the need for further prospective research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.